Abstracts Archive - Page 423 of 1683 - ATC Abstracts

2020 American Transplant Congress
Characteristics of Early BK Viremia after Renal Transplantation at an Urban Academic Medical Center
K. Kurzweil, K. Lamartina, K. Svaflarska, D. Kutrzuba, N. Fayyaz, O. Piatek, P. West-Thielke, Z. Hajjiri, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: BK viremia (BKV) is a deleterious complication after renal transplantation that can compromise allograft function. Centers face the challenge of identifying at-risk patients and…
2020 American Transplant Congress
Effect of JC Virus on Polyomavirus Nephropathy in Renal Transplant Recipients
G. Huang, Y. Huang, X. Chen, J. Qiu, J. Li, C. Wang, L. Chen
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
*Purpose: To investigate the effect of JC virus (JCV) on the development and prognosis of BK virus (BKV) infection and polyomavirus nephropathy (PVN) in renal…
2020 American Transplant Congress
Experiences and Challenges Faced by Organ Transplant Recipients with Donor-Derived Hepatitis C Virus Infection
K. Prakash¹, C. Ramirez-Sanchez¹, S. I. Ramirez¹, C. Logan¹, N. Law¹, K. Mekeel², V. Pretorius², S. Aslam¹
¹Medicine, University of California San Diego, San Diego, CA, ²Surgery, University of California San Diego, San Diego, CA
*Purpose: Recently, transplantation of organs from viremic donors with hepatitis C virus (HCV-V) has increased. Currently, there is a lack of standardization of consent forms…
2020 American Transplant Congress
Osmotic Nephropathy from a Non-Sucrose Based IVIG
S. Reddy, L. Kodali
Nephrology, Mayo Clinic, Phoenix, AZ
*Purpose: We present a case of acute renal failure and hyperkalemia due to osmotic nephropathy from a non-sucrose based IVIG infusion therapy.*Methods: A 67-year-old man…
2020 American Transplant Congress
Polyoma Virus Infection in Renal Transplant Recipients Using Tacrolimo and Everolimo
P. M. Souza¹, C. Ribeiro¹, S. C. Miranda¹, A. S. Alvarenga¹, C. R. Felipe¹, G. Marques¹, G. P. Tarcia¹, L. L. Braga², L. S. Ferreira Boy², M. L. Martins²
¹Nephrology, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil, ²Scientific Technical Development Management, Hemominas Foundation, Belo Horizonte, Brazil
*Purpose: Seropositivity for polyoma virus can reach 80% in kidney transplant recipients, with 1 to 10% polyoma associated nephropathy which negatively influences graft survival. Therefore,…
2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv⁺ Posttransplant Lymphoproliferative Disease (PTLD)
R. Shen¹, N. Guzman-Becerra¹, Y. Sun¹, F. Forozan¹, S. Prockop², E. Doubrovina², R. O'Reilly², X. Li¹, M. Hiremath³, L. Gamelin¹, W. Navarro¹, B. Aftab¹
¹Atara Biotherapeutics, Thousand Oaks, CA, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Atara Biotherapeutics, South San Francisco, CA
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…
2020 American Transplant Congress
Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation
D. Conti¹, D. Schuster¹, M. Garner¹, E. Maciera¹, S. Patel²
¹Albany Medical Center, Albany, NY, ²Surgery, Albany Medical Center, Albany, NY
*Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…
2020 American Transplant Congress
Management of Pancreatic Cancer after Liver Transplantation: A 27-Year Single-Center Experience
I. A. Ziogas, M. A. Rauf, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The occurrence of de novo cancer after liver transplant (LT) is a leading cause of post-LT mortality and can be partially attributed to the…
2020 American Transplant Congress
Hepatitis C and Racial Disparity in Liver Transplant Waitlist Additions: Separate Not Equal
C. Wang¹, J. Buggs¹, E. Rogers¹, A. Kumar², N. Kemmer³
¹Transplant Surgery, Tampa General Hospital, Tampa, FL, ²Morsani College of Medicine, University of South Florida, Tampa, FL, ³Transplant Hepatology, Tampa General Hospital, Tampa, FL
*Purpose: In 2014, direct-acting antivirals (DAAs) became available as a treatment option for Hepatitis C Virus (HCV) with successful results. Since the implementation of DAAs,…
2020 American Transplant Congress
Kidney Transplant Outcomes in Incarcerated End Stage Renal Disease Patients
R. Rattanavich, T. Hoang, R. Villicana
Transplant institute, Loma Linda University, San Bernadino, CA
*Purpose: Kidney transplantation remains the treatment of choice for end stage renal disease as it improves mortality and morbidity. Outcomes of incarcerated ESRD patients who…